


 Cite this: *RSC Adv.*, 2020, **10**, 7855

 Received 21st December 2019
 Accepted 13th February 2020

 DOI: 10.1039/d0ra01352h
rsc.li/rsc-advances

One-pot copper-catalyzed three-component reaction: a modular approach to functionalized 2-quinolones†

 Ah Reum Kim^{ab} and Hee Nam Lim^{ab}  ^{*a}

A copper-catalyzed three-component annulation for the synthesis of functionalized 2-quinolones was developed. Three reactions including an S_N2 , a Knoevenagel, and finally C–N bond formation are involved in the designed cascade reaction using 2-bromoacylarenes, 2-iodoacetamide, and nucleophiles as the three components. A new catalytic system was discovered during the study and this modular approach is highly efficient to access functionalized 2-quinolone derivatives, compatible with a broad range of functional groups, scalable, and step-economic. Further derivatization of the obtained product demonstrates the synthetic utility of this method.

Introduction

2-Quinolones are widely used in the medicinal arena and material science owing to their versatile biological activities¹ and utility as biomaterials² with interesting functions. They are also found as core structures of various natural products.³ For 2-quinolone synthesis, two traditional approaches have been well established: the acid-assisted (Knorr)⁴ or base-promoted synthesis (Friedländer).⁵ However, the harsh acidic conditions in the Knorr type synthesis limits the widespread application of this reaction. In the complementary Friedländer type reaction, 2-aminoacylarenes are common motifs that couple with malonates; this has been a widely used protocol to provide substituted 2-quinolones. In spite of the practicality and scalability, it often requires multi-step pre-functionalization to introduce the amine moiety of arenes or it needs a long process to install functional groups at the target position of quinolones.⁶

As alternative methods, a number of synthetic procedures have been recently demonstrated *via* intermolecular coupling reaction with transition-metal (TM) complexes.^{7–10} Involving C–N bond and/or C–C bond forming reaction, each protocol has provided orthogonal bond formation and broad functional group compatibility for the classical methods. In 2004, Kadnikov and Larock developed Pd-catalyzed three-component annulation using *N*-substituted *o*-iodoanilines, internal

alkynes and CO.^{7a} Alper disclosed in 2014 the preparation of 4-substituted 2-quinolones by the Pd-catalyzed oxidative cyclocarbonylation of *N*-monosubstituted 2-vinylanilines.^{7b} More recently, Jiao and coworkers found a novel Rh-catalyzed carbonylation and annulation of *N*-alkyl anilines with CO and internal alkyne through N–H and C–H activation.^{7c} Consequently, the Wu group succeeded in applying the same strategy with an Ir catalyst, which could now tolerate halogen groups.^{7d} Very recently, Das developed a method to afford 3-substituted 2-quinolones with terminal alkynes and oxalic acid as a CO source under supported Pd-catalysis.^{7e}

In addition to utilizing CO gas or its equivalent, two-component reactions *via* C–H bond activation have also been of much interests. In 2014, Jeganmohan reported a Ru-catalyzed cyclization of anilides with acrylates or propiolates that delivers unsubstituted 2-quinolones or 4-alkyl substituted 2-quinolones, respectively;^{8a} the method involves amide-directed C–H alkenylation followed by an intramolecular amidation. Liu also used acetanilide as a directing group in a Pd-catalyzed cascade reaction, but the directing group was installed from a free aniline with acetic anhydride and acetyl was subsequently removed during the reaction.^{8b} In a similar manner, Maiti and coworkers disclosed a straightforward methodology to afford *N*-aryl-4-substituted quinolones by a Pd-catalyzed dehydrogenative coupling reaction with simple diarylamines and 3-substituted acrylic acids.^{8c} More recently, Yu explored a metal-free/base-promoted lactamization with carbon dioxide and the 2-alkenylanilines.^{8d} In 2015, Rong and Dong developed a unique method using a Rh-catalyzed C–C bond activation strategy to prepare 3,4-disubstituted 2-quinolones from isatins containing various directing groups.⁹ Besides these strategies, benzynes have also been adopted for Pd-catalyzed annulation: the Wang group used α -carbamoyl ketene dithioacetals as

^aEco-Friendly New Materials Research Center, Therapeutics & Biotechnology Division, Korea Research Institute of Chemical Technology (KRICT), 141 Gajeong-ro, Yuseong-gu, Daejeon 34114, Republic of Korea. E-mail: heenam@kRICT.re.kr

^bDepartment of Chemistry, Korea University, 145 Anam-ro, Seongbuk-gu, Seoul 02841, Republic of Korea

† Electronic supplementary information (ESI) available. See DOI: [10.1039/d0ra01352h](https://doi.org/10.1039/d0ra01352h)



coupling partners for C-S/N-H activation^{10a} while the Xu group chose *N*-methoxy acrylamides for C-H/N-H activation.^{10b} Each protocol provides distinct mechanistic insights and useful substrate scope. Nevertheless, introducing various functional groups at the 3 and/or 4-position of 2-quinolones in one-pot from readily available reagents is still an unmet synthetic challenge.

Our interest was to find a convenient and practical protocol for the controlled synthesis of 2-quinolones containing various functional groups with inexpensive copper catalysts and simple starting materials. One viable way is a one-pot coupling reaction between 2-haloacylarenes with pre-functionalized acetamides. Several methods with Pd or Cu metals have been developed in this fashion, but the reported procedures are subject to the substituents at C2 position of the acetamides.¹¹ In this view, a unified strategy to access 3- and/or 4-substituted 2-quinolones in one-pot remains elusive.

Herein, we suggest a one-pot copper-catalyzed three-component reaction¹² as a new strategy for the functionalized 2-quinolone synthesis (Scheme 1). We envisioned that 2-substituted acetamides can be prepared *in situ* from amide 2 and nucleophile 3, which then react with 2-haloacylarenes 1 in the same pot; following this sequence, the unprecedented three-component reaction involving S_N2, Knoevenagel and copper-catalyzed C-N bond coupling reactions can offer 3,4-difunctionalized 2-quinolones by forming three new C-X bonds (X = carbon or heteroatoms). There are many possible reaction pathways to give the desired product 4, however, the actual reaction path is likely dependent on the rate of each reaction. In principle, this modular approach will allow a diverse set of 2-quinolones to be prepared by introducing various nucleophiles. However, the challenge lies in securing high compatibility between three independent reactions in which many reactants might hamper the operation of each reaction or disable the catalytic activity.¹³


Results and discussion

To realize the proposed multicomponent reaction, the commercially available substrates **1a**, **2**, and **3a** were chosen for the model reaction. We initially focused on a catalytic system with CuI and diamine ligands;¹⁴ gratifyingly, it was effective, although the desired product **4aa** was given in only low to moderate yields (30–50%). Despite much efforts, the catalytic system employing this frequently used copper salt was not further improved by adopting various ligands, solvents, nor even by targeting other copper salts with different counter



anions. Inspired by a previous study,^{11c} we next screened copper powder-based catalytic conditions. After significant efforts to optimize the reaction, the use of copper powder (60–80 nm) with 2-picolinic acid (**L1**) and K₂CO₃ was found to be most effective with high reproducibility. It is notable that the combination of copper powder with ligand are rarely reported for synthesis of nitrogen-incorporated small molecules. The selected control experiments during optimization studies are summarized in Table 1.

It was not surprising to observe no conversion without copper powder (entry 2); however, the reaction proceeded without **L1** to give **4aa** in 30% yield (entry 3) and the base was essential (entry 4) with only trace product observed when the base was omitted. This reaction was operative at even lower temperatures, although the efficacy was highly reduced (entry 5). While other less polar solvents such as tetrahydrofuran, chloroform, and 1,4-dioxane were less productive (10–20%), moderate yield (40%) was observed using toluene (entry 6). Although the amount of Cu catalyst can be reduced to 10%, the yield was decreased (entry 7). The choice of ligand proved to be very important for further reaction optimization.¹⁵ A monodentate ligand such as 2,6-lutidine (**L2**) was not as good as **L1** (entry 8). Phenanthroline and bipyridine ligands (**L3** and **L4**) were comparable to **L1** (entry 9 and 10). However, N, O-ligands

Table 1 Reaction optimization for the synthesis of **4aa**



Entry	Variations from standard conditions	Yield ^a
1	None	55% (52) ^b
2	w/o Cu powder	Trace
3	w/o L1	30%
4	w/o K ₂ CO ₃	Trace
5	90 °C instead of 110 °C	21%
6	Other nonpolar solvents instead of DMF	10–40%
7	10 mol% Cu powder and L1 instead of 20%	44%
8	L2 instead of L1	27%
9	L3 instead of L1	48%
10	L4 instead of L1	41%
11	L5 instead of L1	23%
12	L6 instead of L1	14%
13	L7 instead of L1	44%
14	L8 instead of L1	34%




Scheme 1 Proposed three-component approach for 2-quinolone synthesis.

^a Determined by ¹H NMR using 1,3,5-trimethoxybenzene as the internal standard. ^b Isolated yield.

(**L5**, **L6**) were much less efficient (entry 11 and 12).¹⁶ A diamine ligand (DMEDA, **L7**) was also compatible with the copper powder with slightly lower yield (entry 13). It was interesting to observe that the reaction was still working to give a reasonable yield in the presence of an anionic O,O-ligand (**L8**) that contains an active methylene (entry 14).¹⁷

With the optimized conditions in hand, we first tested the functional group compatibility. Gratifyingly, a range of functional groups are well suited in this reaction (Table 2). For example, alkyl and alkoxy substituents worked smoothly, giving moderate to good yields (**4ba**–**4da**). In the case of halides, chloride (**4ea**–**4fa**) showed better yield than fluoride (**4ga**) and a trifluoromethyl group (**4ha**). It is notable that a free hydroxy group was tolerated in the reaction to give a reasonable yield (**4ia**). Electron rich functional groups such as dialkoxy and methylenedioxy were also compatible (**4ja**–**4ka**). The acid-sensitive MOM protecting group (**4la**) and redox-unstable benzyl protecting group (**4ma**) were tolerated in this transformation. A heterocycle such as tetrazole also participated in the three-component reaction. While testing the arene scope, the efficiency of other arylaldehydes containing naphthalene, pyridine, thiophene, and biologically more relevant indole was relatively low (**4oa**–**4ra**), but the products were still obtained in synthetically useful yields. Under the standard conditions, ketones were much less reactive, likely due to inefficient Knoevenagel condensation. In this case, additional use of $\text{Ca}(\text{OH})_2$ was discovered to promote the reaction while the driving force is unclear. The optimization process for the ketone substrate is summarized (see the page S3 in the ESI†). In this way, 3,4-disubstituted 2-quinolones were also accessible, offering the facile entry to densely functionalized derivatives (**4sa**–**4wa**).

Table 2 Acylarene scope^a




^a Run in **1** (0.5 mmol), **2** (0.75 mmol), **3a** (0.75 mmol) scale. ^b **1** (0.5 mmol), **2** (1.0 mmol), **3a** (1.0 mmol), K_2CO_3 (2.5 mmol), and $\text{Ca}(\text{OH})_2$ (2.5 mmol) were used.


Next, the reaction scope with respect to sulfinates was surveyed (Table 3). Various arylsulfinic acid sodium salts¹⁸ containing both electron-donating and -withdrawing groups were examined (**4ab**–**4ae**), all of which were amenable to the reaction. When alkyl sulfinates containing methyl, ethyl, cyclopropyl, and cyclohexyl groups (**4af**–**4ai**) were employed, more lipophilic quinolones were obtained. The scope was further extended to other heterocycles: both picoline and thiophene rings (**4aj**–**4ak**) survived to give the corresponding products albeit in low yield for the picoline substrate. To our delight, the reaction with 10-camphorsulfinic acid sodium salt proceeded smoothly to provide **4al**.

Given the success using sulfinates, other nucleophiles were next examined (Scheme 2a). When sodium thiolate was employed in the standard condition, 3-phenylthio-2-quinolone 5 was obtained in only 30% isolated yield; however, the yield was improved by adding $\text{Ca}(\text{OH})_2$ (55%). In addition to sulfur(II), oxygen-based nucleophiles such as sodium phenoxides also worked in the presence of a stronger base, thus affording 3-aryloxy-2-quinolones 6. Notably, the use of nitrogen-based nucleophile, *N*-methylphenylamine, resulted in the desired transformation using ketone substrate **1r**, giving the 2-quinolone **7** in 44% yield.¹⁹ However, the use of other amine nucleophiles such as aniline and dialkylamines was unsuccessful. In addition, the application of the carbon-based soft nucleophiles such as malonates remains unresolved.

The protocol was readily scalable (Scheme 2b); in the gram scale reaction **4aa** was obtained with improved efficiency (52% → 62%). Next, we demonstrated the synthetic utility of the prepared quinolones (Scheme 2c). As **4aa** holds many useful functional groups, it could be further functionalized. For instance, it was successfully transformed to 2-chloroquinoline **8**. *N*-Benzyl quinolone **9** was obtained by the selective *N*-alkylation in good yield, and **9** could be further functionalized to 3,4-disubstituted hydroquinolone **10** by Grignard-initiated Michael addition.²⁰ Meanwhile, the sulfonyl group can be converted to

Table 3 Sulfinate scope






Scheme 2 Further scope and applications. (a) Use of other nucleophiles. (b) Gram scale. (c) Further applications.

organotin compound **11**²¹ which is a key intermediate for the synthesis of 3-halogenated quinolones **12**²² and **13**²³ and is expected as a useful platform for coupling reactions.²⁴ The versatile conversion of the product obtained by our method is believed to have many implications in synthetic and medicinal chemistry.

Possible mechanistic pathways to give **4aa** are illustrated in Scheme 3a. Depending on the reaction order, they can be classified into three ways. The first route (path A) is deconstructive as the resulting intermediate **I** cannot afford **4aa**. The second route is firstly forming the intermediate **II** by C–N coupling reaction: paths B and C are conceivable to give **4aa**. The third route is initiated by a S_N2 reaction between **2** and **3a**, which provides the intermediate **V**. The intermediate **V** can form **4aa** by reacting with **1a** via the intermolecular C–N bond formation followed by the Knoevenagel condensation (path D) or *vise versa* (path E).

The reaction with **1a**, **2**, and **3a** was monitored by checking tlc, tracking LC-MS and ¹H nmr experiment; we found no LC traces corresponding to **I**, **II**, **III**, and **IV**. On the other hand, the intermediate **V** was clearly identified while **2** was fully consumed within 1 hour. This indicates that the reaction quickly proceeds into a two-component reaction (**1a** and **V**). In



Scheme 3 A proposed mechanism. (a) Possible reaction pathways. (b) Control experiments.

addition, the intermediate **VI** was found as a major resting intermediate in the LC-trace and tlc during the entire course of the reaction. Although the intermediate **IV** was not detected in the LC-trace, a possibility cannot be excluded that the intramolecular Knoevenagel reaction rapidly occurs, thus not allowing **VI** itself to stay on.

To gain insights into the mechanism, we first conducted a control experiment using **1a** and **V** under the standard conditions [Scheme 3b-(1)]. Interestingly, in this two-component reaction, the yield of **4aa** was even lower than that of the three-component reaction. The only difference was the presence of NaI which is a by-product by S_N2 reaction between **2** and **3a**; NaI was indeed an important promoter of the three-component reaction [Scheme 3b-(2)].²⁵ As expected, the compounds **II** and **III** were not formed in the control experiment [Scheme 3b-(3)]. The intermediate **IV** was highly reactive species. We attempted to isolate the intermediate **IV** by treating **II** with **3a**. However, a isolated product was **4aa** and **IV** was not traceable [Scheme 3b-(4)]. This observation, in part, supports feasibility of path D if C–N bond forming reaction is facile. The formation of **15** in the Scheme 3b-(5) further supports our postulate about the path D while the efficiency for C–N bond formation was low. Although not completely conclusive, at this point, path E (major contribution) and D (minor contribution) are plausible pathways to **4aa**.

Conclusions

In conclusion, under the conceptually simple one-pot operation, three separate reagents reacted to synergistically form the



functionalized 2-quinolones. This was enabled by three cascade reactions of S_N2 , Knoevenagel condensation, and C–N coupling with good control over reactive intermediates. During reaction optimization, a new catalytic system employing copper power with 2-picolinic acid was discovered and this method highlights streamlined preparation of biologically important 2-quinolone derivatives. Studies to further extend the reaction scope of acyl groups, arenes and nucleophiles is underway in our laboratory.

Experimental section

General remarks

All reactions were carried out in 5 mL capped vials. *N,N*-Dimethylformamide (DMF) was directly used from SPS system (Hansen, Puresolve MD) without further purification. Thin layer chromatography (TLC) analysis was run on silica gel plates. Spots were visualized by exposure to ultraviolet (UV) light (254 nm). High-resolution mass spectra were reported for the molecular ion $[M]^+$. Melting points were determined with the Mettler Toledo MP50 and the values were uncorrected. Nuclear magnetic resonance (NMR) spectra were recorded with a Bruker (400 MHz for 1H , 100 MHz for ^{13}C and 376 MHz for ^{19}F). Chemical shifts for proton NMR spectra are reported in parts per million (ppm) relative to the singlet at 7.26 ppm for chloroform-*d* and to the quintet at 2.50 ppm for dimethylsulfoxide-*d*₆. Chemical shifts for carbon NMR spectra are reported in 77.2 ppm with the center line of triplet for chloroform-*d*, in 39.5 ppm with the center line of the septet for dimethylsulfoxide-*d*₆ and in 116.6 ppm, 164.2 ppm with the center line of the quartet for trifluoroacetic acid-*d*. Data for 1H NMR were presented as following: chemical shifts (δ , ppm), multiplicity (br = broad, s = singlet, d = doublet, t = triplet, dd = doublet of doublets, td = triplet of doublet, m = multiplet), coupling constant (Hz), and integration. The chemical shifts of peaks found were reported for ^{13}C NMR spectra. Infrared spectra were recorded with a Smith Detection ATR-FTIR.

2-Bromo-5-((1-methyl-1*H*-tetrazol-5-yl)methoxy)benzaldehyde (1n)

A mixture of 2-bromo-5-hydroxybenzaldehyde (1.00 g, 5.0 mmol), K_2CO_3 (1.04 g, 7.5 mmol) and 5-(chloromethyl)-1-methyl-1*H*-tetrazole (0.79 g, 6.0 mmol) in DMSO (10 mL) was stirred at 50 °C for 4 h. Then, the reaction mixture was cooled to room temperature, quenched with saturated NH_4Cl solution, and extracted with EtOAc (30 × 3 mL). The organic solution was dried over $MgSO_4$, concentrated, and subjected to column chromatography (Hex : EtOAc = 3 : 1) to afford the benzaldehyde **1n** (1.02 g, 69%) as white solid, mp 66–67 °C.

R_f = 0.2 (Hex : EtOAc = 3 : 1); 1H NMR (400 MHz, $CDCl_3$ -*d*) δ 4.37 (s, 3H), 5.35 (s, 2H), 7.15 (dd, J = 8.8 Hz and 3.1 Hz, 1H), 7.54–7.56 (m, 2H), 10.29 (s, 1H). ^{13}C NMR (100 MHz, $CDCl_3$ -*d*) δ 39.8, 61.2, 114.1, 119.0, 123.7, 134.2, 135.0, 157.7, 162.1, 191.6. IR (neat) ν_{max} 1010, 1162, 1224, 1684, 2876, 3066 cm^{-1} . HRMS [EI $^+$] calcd for $C_{10}H_9BrN_4O_2$ [M] $^+$ 295.9909, found 295.9904.

General procedure for 4aa–4ra (Table 1) and 4ab–4al (Table 2)

A 5 mL vial was charged with 2-bromobenzaldehyde **1** (0.50 mmol), 2-iodoacetamide **2** (138.7 mg, 0.75 mmol), a corresponding sodium sulfinate **3** (0.75 mmol), Cu powder (60–80 nm, 6.4 mg, 0.10 mmol), 2-picolinic acid (12.3 mg, 0.10 mmol), K_2CO_3 (138.2 mg, 1.00 mmol) in dry DMF (1.5 mL). The vial was sealed with the cap and heated at 110 °C under stirring for 48 h. After cooling to room temperature, the reaction mixture was diluted with saturated NH_4Cl solution and extracted with ethyl acetate (20 × 5 mL). The combined organic solution was dried over $MgSO_4$ and concentrated. The residue was subjected to silica gel column chromatography (DCM : MeOH = 97 : 3 to 95 : 5 or Hex : EtOAc = 1 : 1) to afford the 2-quinolones.

Purification process for 4qa (Table 1)

After cooling to room temperature, the resulting brownish suspension was filtered and washed with saturated aq. NH_4Cl solution. The dark yellow solid was then washed with H_2O , MeOH, and DCM to afford the compound **4qa** (light yellow solid).

General procedure for 4sa–4wa (ketone substrates in Table 1)

A 5 mL vial was charged with ketone **1s–1w** (0.50 mmol), 2-iodoacetamide **2** (185.0 mg, 1.00 mmol), sodium benzenesulfinate **3a** (164.2 mg, 1.00 mmol), Cu powder (60–80 nm, 6.4 mg, 0.10 mmol), 2-picolinic acid (12.3 mg, 0.10 mmol), K_2CO_3 (172.8 mg, 1.25 mmol), and $Ca(OH)_2$ (92.6 mg, 1.25 mmol) in dry DMF (1.5 mL). The vial was sealed with the cap and heated at 110 °C under stirring for 48 h. After cooling to room temperature, the reaction mixture was diluted with saturated aq. NH_4Cl solution and extracted with ethyl acetate (20 × 5 mL). The combined organic solution was dried over $MgSO_4$ and concentrated, and subjected to silica gel column chromatography (DCM : MeOH = 97 : 3 to 95 : 5 or Hex : EtOAc = 1 : 1) to afford the 2-quinolones.

3-(Phenylsulfonyl)quinolin-2(1*H*)-one (4aa)

Yield = 52%; white solid; 1H NMR (400 MHz, $DMSO-d_6$) δ 7.30 (t, J = 7.6 Hz, 1H), 7.35 (d, J = 8.4 Hz, 1H), 7.59–7.63 (m, 2H), 7.66–7.73 (m, 2H), 7.99–8.04 (m, 3H), 8.97 (s, 1H), 12.17 (s, 1H). This spectral data is in agreement with the reported ref. 11c.

7-Methyl-3-(phenylsulfonyl)quinolin-2(1*H*)-one (4ba)

Yield = 62%; white solid; mp \geq 300 °C; R_f = 0.3 (DCM : MeOH = 93 : 7) 1H NMR (400 MHz, $DMSO-d_6$) δ 2.40 (s, 3H), 7.13–7.15 (m, 2H), 7.58–7.62 (m, 2H), 7.70 (m, 1H), 7.90 (m, 1H), 7.98–8.01 (m, 2H), 8.91 (s, 1H), 12.18 (s, 1H). ^{13}C NMR (100 MHz, $DMSO-d_6$) δ 21.7, 114.9, 115.1, 124.4, 128.3, 128.9, 129.4, 130.4, 133.6, 139.8, 141.2, 144.4, 145.0, 156.5. IR (neat) ν_{max} 1155, 1308, 1478, 1603, 1649, 3144 cm^{-1} . HRMS [EI $^+$] calcd for $C_{16}H_{13}NO_3S$ [M] $^+$ 299.0616, found 299.0626.



6-Methoxy-3-(phenylsulfonyl)quinolin-2(1*H*)-one (4ca)

Yield = 56%; pale yellow solid; mp ≥ 300 °C; R_f = 0.25 (DCM : MeOH = 93 : 7) 1 H NMR (400 MHz, DMSO-*d*₆) δ 3.81 (s, 3H), 7.28–7.36 (m, 2H), 7.59–7.63 (m, 3H), 7.70 (m, 1H), 7.99–8.01 (m, 2H), 8.92 (s, 1H), 12.16 (s, 1H). 13 C NMR (100 MHz, DMSO-*d*₆) δ 55.6, 110.9, 116.8, 117.7, 124.0, 128.4, 128.9, 130.9, 133.6, 135.8, 139.6, 144.0, 154.6, 155.9. IR (neat) ν _{max} 1151, 1291, 1493, 1618, 1649, 3401 cm^{−1}. HRMS[EI^+] calcd for C₁₆H₁₃NO₄S [M]⁺ 315.0565, found 315.0570.

6-(Pentyloxy)-3-(phenylsulfonyl)quinolin-2(1*H*)-one (4da)

Yield = 50%; pale yellow solid; mp 279–280 °C; R_f = 0.25 (DCM : MeOH = 93 : 7) 1 H NMR (400 MHz, DMSO-*d*₆) δ 0.90 (t, J = 6.9 Hz, 3H), 1.30–1.44 (m, 4H), 1.71–1.77 (m, 2H), 4.00 (t, J = 6.5 Hz, 2H), 7.27–7.35 (m, 2H), 7.58–7.63 (m, 3H), 7.70 (t, J = 7.4 Hz, 1H), 8.00 (d, J = 7.8 Hz, 2H), 8.90 (s, 1H), 12.14 (s, 1H). 13 C NMR (100 MHz, DMSO-*d*₆) δ 13.9, 21.9, 27.7, 28.2, 68.0, 111.5, 116.7, 117.8, 124.3, 128.4, 128.9, 130.9, 133.6, 135.7, 139.7, 144.0, 153.9, 155.9. IR (neat) ν _{max} 1150, 1289, 1474, 1619, 1648, 3085 cm^{−1}. HRMS[EI^+] calcd for C₂₀H₂₁NO₄S [M]⁺ 371.1191, found 371.1187.

5-Chloro-3-(phenylsulfonyl)quinolin-2(1*H*)-one (4ea)

Yield = 32%; pale yellow solid; mp ≥ 300 °C; R_f = 0.4 (DCM : MeOH = 93 : 7) 1 H NMR (400 MHz, DMSO-*d*₆) δ 7.33 (d, J = 8.5 Hz, 1H), 7.46 (d, J = 7.8 Hz, 1H), 7.60–7.74 (m, 4H), 8.03–8.05 (m, 2H), 8.95 (s, 1H), 12.54 (s, 1H). 13 C NMR (100 MHz, DMSO-*d*₆) δ 114.8, 115.1, 123.3, 128.7, 129.0, 131.9, 133.1, 134.0, 134.7, 139.0, 139.7, 142.5, 156.0. IR (neat) ν _{max} 1155, 1319, 1444, 1571, 1612, 3078 cm^{−1}. HRMS[EI^+] calcd for C₁₅H₁₀ClNO₃S [M]⁺ 319.0070, found 319.0065.

6-Chloro-3-(phenylsulfonyl)quinolin-2(1*H*)-one (4fa)

Yield = 45%; ivory solid; mp ≥ 300 °C; R_f = 0.25 (DCM : MeOH = 93 : 7) 1 H NMR (400 MHz, DMSO-*d*₆) δ 7.35 (d, J = 8.9 Hz, 1H), 7.59–7.63 (t, J = 7.6 Hz, 2H), 7.69–7.73 (m, 2H), 8.00 (d, J = 7.6 Hz, 2H), 8.16 (d, J = 1.8 Hz, 1H), 8.97 (s, 1H), 12.36 (s, 1H). 13 C NMR (100 MHz, DMSO-*d*₆) δ 117.4, 118.3, 126.5, 128.5, 129.0, 129.3, 131.8, 133.7, 133.8, 139.3, 139.8, 143.7, 156.2. IR (neat) ν _{max} 1158, 1312, 1477, 1617, 1649, 3455 cm^{−1}. HRMS[EI^+] calcd for C₁₅H₁₀ClNO₃S [M]⁺ 319.0070, found 318.9950.

6-Fluoro-3-(phenylsulfonyl)quinolin-2(1*H*)-one (4ga)

Yield = 29%; ivory solid; mp ≥ 300 °C; R_f = 0.25 (DCM : MeOH = 93 : 7) 1 H NMR (400 MHz, DMSO-*d*₆) δ 7.38 (dd, J = 9.1 and 4.6 Hz, 1H), 7.58–7.63 (m, 3H), 7.71 (m, 1H), 7.93 (dd, J = 8.9 and 2.8 Hz, 1H), 8.00 (d, J = 7.5 Hz, 2H), 8.98 (s, 1H), 12.32 (s, 1H). 13 C NMR (100 MHz, DMSO-*d*₆) δ 114.9 (d, $J_{C,F}$ = 23 Hz), 117.5 (d, $J_{C,F}$ = 8 Hz), 117.8 (d, $J_{C,F}$ = 10 Hz), 122.4 (d, $J_{C,F}$ = 25 Hz), 128.5, 129.0, 131.9, 133.8, 137.9, 139.4, 143.9 (d, $J_{C,F}$ = 4 Hz), 156.1, 157.1 (d, $J_{C,F}$ = 238 Hz). 19 F NMR (376 MHz, DMSO-*d*₆) δ −119.7. IR (neat) ν _{max} 1158, 1312, 1498, 1628, 1650, 3073 cm^{−1}. HRMS[EI^+] calcd for C₁₅H₁₀FNO₃S [M]⁺ 303.0365, found 303.0356.

3-(Phenylsulfonyl)-6-(trifluoromethyl)quinolin-2(1*H*)-one (4ha)

Yield = 32%; white solid; mp ≥ 300 °C; R_f = 0.3 (DCM : MeOH = 93 : 7) 1 H NMR (400 MHz, DMSO-*d*₆) δ 7.50 (d, J = 8.7 Hz, 1H), 7.60–7.64 (m, 2H), 7.72 (m, 1H), 7.96–8.05 (m, 3H), 8.54 (s, 1H), 9.13 (s, 1H), 12.55 (s, 1H). 13 C NMR (100 MHz, DMSO-*d*₆) δ 116.6, 116.8, 123.0 (q, $J_{C,F}$ = 32 Hz), 124.0 (q, $J_{C,F}$ = 270 Hz), 128.4 (q, $J_{C,F}$ = 4 Hz), 128.5, 129.0, 129.7 (q, $J_{C,F}$ = 3 Hz) 132.1, 133.9, 139.3, 143.3, 144.6, 156.5. 19 F NMR (376 MHz, DMSO-*d*₆) δ −60.4. IR (neat) ν _{max} 1126, 1324, 1482, 1631, 1654, 3157 cm^{−1}. HRMS[EI^+] calcd for C₁₆H₁₀F₃NO₃S [M]⁺ 353.0333, found 353.0315.

6-Hydroxy-3-(phenylsulfonyl)quinolin-2(1*H*)-one (4ia)

Yield = 30%; yellow solid; mp ≥ 300 °C; R_f = 0.15 (DCM : MeOH = 93 : 7) 1 H NMR (400 MHz, DMSO-*d*₆) δ 7.18–7.24 (m, 2H), 7.30 (s, 1H), 7.58–7.62 (m, 2H), 7.69 (t, J = 7.4 Hz, 1H), 7.99 (d, J = 7.8 Hz, 2H), 8.84 (s, 1H), 9.74 (s, 1H), 12.04 (s, 1H). 13 C NMR (100 MHz, DMSO-*d*₆) δ 113.2, 116.6, 118.0, 124.1, 128.4, 128.9, 130.7, 133.6, 134.6, 139.8, 143.9, 152.7, 155.8. IR (neat) ν _{max} 1151, 1302, 1413, 1627, 1658, 3433 cm^{−1}. HRMS[EI^+] calcd for C₁₅H₁₁NO₄S [M]⁺ 301.0409, found 301.0410.

7-Dimethoxy-3-(phenylsulfonyl)quinolin-2(1*H*)-one (4ja)

Yield = 39%; pale yellow solid; mp ≥ 300 °C; R_f = 0.15 (DCM : MeOH = 93 : 7) 1 H NMR (400 MHz, DMSO-*d*₆) δ 3.81 (s, 3H), 3.84 (s, 3H), 6.85 (s, 1H), 7.54 (s, 1H), 7.57–7.61 (m, 2H), 7.68 (m, 1H), 7.97–8.00 (m, 2H), 8.80 (s, 1H), 12.04 (s, 1H). 13 C NMR (100 MHz, DMSO-*d*₆) δ 55.8, 55.9, 97.1, 110.1, 110.6, 126.9, 128.2, 128.8, 133.4, 138.1, 140.1, 143.4, 145.6, 155.1, 156.3. IR (neat) ν _{max} 1148, 1252, 1413, 1617, 1649, 3015 cm^{−1}. HRMS[EI^+] calcd for C₁₇H₁₅NO₅S [M]⁺ 345.0671, found 345.0688.

7-(Phenylsulfonyl)-[1,3]dioxolo[4,5-g]quinolin-6(5*H*)-one (4ka)

Yield = 36%; pale brown solid; mp ≥ 300 °C; R_f = 0.2 (DCM : MeOH = 93 : 7) 1 H NMR (400 MHz, DMSO-*d*₆) δ 6.17 (s, 2H), 6.82 (s, 1H), 7.49 (s, 1H), 7.57–7.61 (m, 2H), 7.68 (t, J = 7.3 Hz, 1H), 7.98 (d, J = 7.4 Hz, 2H), 8.78 (s, 1H), 12.15 (s, 1H). 13 C NMR (100 MHz, DMSO-*d*₆) δ 94.8, 102.6, 106.6, 111.8, 126.9, 128.2, 128.8, 133.4, 139.6, 140.0, 143.6, 144.1, 153.3, 156.3. IR (neat) ν _{max} 1152, 1245, 1444, 1629, 1650, 2933 cm^{−1}. HRMS[EI^+] calcd for C₁₆H₁₁NO₅S [M]⁺ 329.0358, found 329.0357.

6-(Methoxymethoxy)-3-(phenylsulfonyl)quinolin-2(1*H*)-one (4la)

Yield = 46%; pale yellow solid; mp 239–240 °C; R_f = 0.2 (DCM : MeOH = 93 : 7); 1 H NMR (400 MHz, DMSO-*d*₆) δ 3.39 (s, 3H), 5.23 (s, 2H), 7.31 (d, J = 9.0 Hz, 1H), 7.42 (dd, J = 9.0 and 2.3 Hz, 1H), 7.58–7.62 (m, 2H), 7.67–7.71 (m, 2H), 8.00 (d, J = 7.8 Hz, 2H), 8.91 (s, 1H), 12.18 (s, 1H). 13 C NMR (100 MHz, DMSO-*d*₆) δ 55.7, 94.3, 114.9, 116.7, 117.7, 124.9, 128.4, 128.9, 131.1, 133.7, 136.4, 139.6, 144.1, 151.8, 156.0. IR (neat) ν _{max} 1152, 1312, 1495, 1625, 1649, 3144 cm^{−1}. HRMS[EI^+] calcd for C₁₇H₁₅NO₅S [M]⁺ 345.0671, found 345.0671.



6-(Benzylxyloxy)-3-(phenylsulfonyl)quinolin-2(1*H*)-one (4ma)

Yield = 45%; yellow solid; mp ≥ 300 °C; R_f = 0.2 (DCM : MeOH = 93 : 7); ^1H NMR (400 MHz, DMSO- d_6) δ 5.15 (s, 2H), 7.29–7.36 (m, 2H), 7.39–7.44 (m, 3H), 7.48–7.50 (m, 2H), 7.59–7.62 (m, 2H), 7.68–7.72 (m, 2H), 8.00 (d, J = 7.8 Hz, 2H), 8.90 (s, 1H), 12.18 (s, 1H). ^{13}C NMR (100 MHz, DMSO- d_6) δ 69.8, 112.2, 116.8, 117.7, 124.4, 127.9, 128.0, 128.4, 128.5, 128.9, 131.0, 133.7, 135.9, 136.6, 139.6, 143.9, 153.6, 156.0. IR (neat) ν_{max} 1149, 1293, 1498, 1622, 1654, 3149 cm $^{-1}$. HRMS[EI^+] calcd for $\text{C}_{22}\text{H}_{17}\text{NO}_4\text{S}$ [M] $^+$ 391.0878, found 391.0870.

6-((1-Methyl-1*H*-tetrazol-5-yl)methoxy)-3-(phenylsulfonyl)quinolin-2(1*H*)-one (4na)

Yield = 50%; pale yellow solid; mp 274–275 °C; R_f = 0.1 (DCM : MeOH = 93 : 7); ^1H NMR (400 MHz, DMSO- d_6) δ 4.40 (s, 3H), 5.42 (s, 2H), 7.32 (d, J = 9.1 Hz, 1H), 7.44 (dd, J = 9.1 and 2.8 Hz, 1H), 7.59–7.63 (m, 2H), 7.68–7.75 (m, 2H), 8.01 (d, J = 7.8 Hz, 2H), 8.89 (s, 1H), 12.20 (s, 1H). ^{13}C NMR (100 MHz, DMSO- d_6) δ 39.6, 60.7, 112.6, 116.9, 117.6, 124.1, 128.4, 128.9, 131.1, 133.7, 136.3, 139.6, 143.9, 152.9, 156.0, 161.8. IR (neat) ν_{max} 1153, 1290, 1493, 1624, 1658, 3015 cm $^{-1}$. HRMS[EI^+] calcd for $\text{C}_{18}\text{H}_{15}\text{N}_5\text{O}_4\text{S}$ [M] $^+$ 397.0845, found 397.0852.

3-(Phenylsulfonyl)benzo[h]quinolin-2(1*H*)-one (4oa)

Yield = 40%; pale brown solid; mp ≥ 300 °C; R_f = 0.3 (DCM : MeOH = 93 : 7); ^1H NMR (400 MHz, DMSO- d_6) δ 7.61–7.65 (m, 3H), 7.69–7.74 (m, 3H), 7.92 (d, J = 8.6 Hz, 1H), 7.98 (d, J = 8.0 Hz, 1H), 8.07 (d, J = 7.7 Hz, 2H), 8.84 (d, J = 8.3 Hz, 1H), 9.04 (s, 1H), 12.59 (s, 1H). ^{13}C NMR (100 MHz, DMSO- d_6) δ 113.7, 120.9, 123.2, 123.3, 126.2, 127.0, 128.4, 128.6, 128.9, 129.6, 129.7, 133.7, 135.1, 139.5, 139.7, 145.0, 157.1. IR (neat) ν_{max} 1150, 1308, 1508, 1627, 1644, 3059 cm $^{-1}$. HRMS[EI^+] calcd for $\text{C}_{19}\text{H}_{13}\text{NO}_3\text{S}$ [M] $^+$ 335.0616, found 335.0614.

3-(Phenylsulfonyl)-1,8-naphthyridin-2(1*H*)-one (4pa)

Yield = 31%; pale yellow solid; mp ≥ 300 °C; R_f = 0.2 (DCM : MeOH = 93 : 7); ^1H NMR (400 MHz, DMSO- d_6) δ 7.37 (m, 1H), 7.60–7.64 (m, 2H), 7.72 (t, J = 7.4 Hz, 1H), 8.00–8.02 (m, 2H), 8.48 (m, 1H), 8.67 (m, 1H), 9.02 (s, 1H), 12.71 (s, 1H). ^{13}C NMR (100 MHz, DMSO- d_6) δ 112.6, 119.3, 128.5, 129.0, 131.8, 133.8, 139.3, 139.5, 144.2, 151.2, 154.1, 157.2. IR (neat) ν_{max} 1147, 1304, 1470, 1608, 1646, 3020 cm $^{-1}$. HRMS[EI^+] calcd for $\text{C}_{14}\text{H}_{10}\text{N}_2\text{O}_3\text{S}$ [M] $^+$ 286.0412, found 286.0396.

9-Methyl-3-(phenylsulfonyl)-1,9-dihydro-2*H*-pyrido[2,3-*b*]indol-2-one (4qa)

Yield = 42%; yellow solid; mp ≥ 300 °C; R_f = 0.2 (DCM : MeOH = 93 : 7); ^1H NMR (400 MHz, DMSO- d_6) δ 3.92 (s, 3H), 7.14 (t, J = 7.5 Hz, 1H), 7.50 (t, J = 7.8 Hz, 1H), 7.57–7.62 (m, 3H), 7.67 (t, J = 7.3 Hz, 1H) 8.02 (d, J = 7.7 Hz, 2H), 8.08 (d, J = 8.2 Hz, 1H), 8.76 (s, 1H), 12.99 (s, 1H). ^{13}C NMR (100 MHz, TFA- d) δ 30.8, 112.8, 115.4, 123.7, 124.9, 130.1, 130.3, 130.8, 131.9, 133.7, 135.7, 137.7, 140.0, 147.4, 156.8. IR (neat) ν_{max} 1090, 1154, 1306, 1555, 1616, 1641 cm $^{-1}$. HRMS[EI^+] calcd for $\text{C}_{18}\text{H}_{14}\text{N}_2\text{O}_3\text{S}$ [M] $^+$ 338.0725, found 338.0732.

6-(Phenylsulfonyl)thieno[3,2-*b*]pyridin-5(4*H*)-one (4ra)

Yield = 23%; pale brown solid; mp 259–260 °C; R_f = 0.1 (DCM : MeOH = 93 : 7); ^1H NMR (400 MHz, DMSO- d_6) δ 7.04 (d, J = 5.4 Hz, 1H), 7.56–7.60 (m, 2H), 7.67 (t, J = 7.3 Hz, 1H), 7.98 (d, J = 7.7 Hz, 2H), 8.23 (d, J = 5.4 Hz, 1H), 9.04 (s, 1H), 12.72 (s, 1H). ^{13}C NMR (100 MHz, DMSO- d_6) δ 115.9, 116.6, 125.3, 128.2, 128.8, 133.3, 139.2, 139.3, 140.1, 147.6, 156.8. IR (neat) ν_{max} 1152, 1312, 1441, 1631, 1641, 3102 cm $^{-1}$. HRMS[EI^+] calcd for $\text{C}_{13}\text{H}_9\text{NO}_3\text{S}_2$ [M] $^+$ 291.0024, found 291.0022.

4-Methyl-3-(phenylsulfonyl)quinolin-2(1*H*)-one (4sa)

Yield = 53%; white solid; mp 282–283 °C; R_f = 0.25 (DCM : MeOH = 93 : 7); ^1H NMR (400 MHz, DMSO- d_6) δ 3.11 (s, 3H), 7.29–7.32 (m, 2H), 7.54–7.58 (m, 2H), 7.63–7.67 (m, 2H), 7.94–7.96 (m, 2H), 8.09 (m, 1H), 11.98 (s, 1H). ^{13}C NMR (100 MHz, DMSO- d_6) δ 14.8, 115.7, 119.0, 122.6, 126.9, 127.4, 128.5, 128.9, 132.9, 133.3, 139.3, 142.4, 154.6, 156.7. IR (neat) ν_{max} 1143, 1302, 1497, 1636, 1653, 2840 cm $^{-1}$. HRMS[EI^+] calcd for $\text{C}_{16}\text{H}_{13}\text{NO}_3\text{S}$ [M] $^+$ 299.0616, found 299.0613.

4-Cyclopropyl-3-(phenylsulfonyl)quinolin-2(1*H*)-one (4ta)

Yield = 68%; pale yellow solid; mp 261–262 °C; R_f = 0.3 (DCM : MeOH = 93 : 7); ^1H NMR (400 MHz, DMSO- d_6) δ 0.75–0.79 (m, 2H), 1.32–1.37 (m, 2H), 2.46 (m, 1H), 7.26–7.32 (m, 2H), 7.51–7.55 (m, 2H), 7.60–7.64 (m, 2H), 7.91 (d, J = 7.6 Hz, 2H), 8.35 (d, J = 8.3 Hz, 1H), 11.99 (s, 1H). ^{13}C NMR (100 MHz, DMSO- d_6) δ 10.2, 12.8, 115.7, 119.9, 122.3, 127.6, 127.9, 128.3, 132.1, 132.6, 132.8, 139.2, 143.0, 156.8, 158.6. IR (neat) ν_{max} 1159, 1314, 1593, 1637, 2847, 2995 cm $^{-1}$. HRMS[EI^+] calcd for $\text{C}_{18}\text{H}_{15}\text{NO}_3\text{S}$ [M] $^+$ 325.0773, found 352.0776.

4-Phenyl-3-(phenylsulfonyl)quinolin-2(1*H*)-one (4ua)

Yield = 55%; pale white solid; mp 287–288 °C; R_f = 0.35 (DCM : MeOH = 93 : 7); ^1H NMR (400 MHz, DMSO- d_6) δ 6.87 (d, J = 8.3 Hz, 1H), 7.13 (t, J = 7.7 Hz, 1H), 7.37 (d, J = 8.3 Hz, 1H), 7.40–7.42 (m, 2H), 7.50–7.57 (m, 5H), 7.61–7.66 (m, 2H), 7.89 (d, J = 7.6 Hz, 2H), 12.18 (s, 1H). ^{13}C NMR (100 MHz, DMSO- d_6) δ 115.5, 119.5, 122.6, 127.7, 127.9, 128.1, 128.5, 128.6, 128.8, 133.0, 133.5, 134.4, 139.9, 141.6, 155.9, 156.7. IR (neat) ν_{max} 1149, 1306, 1653, 2851, 2876, 2982 cm $^{-1}$. HRMS[EI^+] calcd for $\text{C}_{21}\text{H}_{15}\text{NO}_3\text{S}$ [M] $^+$ 361.0773, found 361.0791.

3-(Phenylsulfonyl)-4-(thiophen-2-yl)quinolin-2(1*H*)-one (4va)

Eluent used for the chromatography (Hex : EtOAc = 1 : 1); yield = 41%; gray solid; mp 250–251 °C; R_f = 0.3 (Hex : EtOAc = 1 : 1); ^1H NMR (400 MHz, CDCl_3 - d) δ 7.19–7.22 (m, 2H), 7.23–7.27 (m, 2H), 7.36 (d, J = 8.2 Hz, 1H), 7.46–7.49 (m, 2H), 7.54 (t, J = 7.2 Hz, 1H), 7.62–7.65 (m, 2H), 8.11 (d, J = 7.7 Hz, 2H), 12.78 (s, 1H). ^{13}C NMR (100 MHz, CDCl_3 - d) δ 116.3, 121.2, 123.7, 127.2, 127.5, 128.4, 128.9, 129.2, 129.2, 131.2, 132.7, 133.2, 133.7, 139.2, 141.7, 150.8, 159.4. IR (neat) ν_{max} 1145, 1309, 1637, 1653, 2845, 3109 cm $^{-1}$. HRMS[EI^+] calcd for $\text{C}_{19}\text{H}_{13}\text{NO}_3\text{S}_2$ [M] $^+$ 367.0337, found 367.0339.



N,N-Diethyl-2-oxo-3-(phenylsulfonyl)-1,2-dihydroquinoline-4-carboxamide (4wa)

Eluent for the chromatography (Hex : EtOAc = 2 : 1 to 3 : 7); yield = 43%; pale white solid; mp 214–215 °C; R_f = 0.3 (Hex : EtOAc = 1 : 2); ^1H NMR (400 MHz, CDCl_3 -*d*) δ 1.12 (t, J = 7.1 Hz, 3H), 1.42 (t, J = 7.1 Hz, 3H), 3.27–3.40 (m, 2H), 3.65 (m, 1H), 3.86 (m, 1H), 7.26–7.31 (m, 2H), 7.45–7.49 (m, 2H), 7.54 (t, J = 7.3 Hz, 1H), 7.62–7.66 (m, 2H), 8.23–8.25 (m, 2H), 12.65 (s, 1H). ^{13}C NMR (100 MHz, CDCl_3 -*d*) δ 12.2, 13.2, 39.0, 43.5, 116.3, 116.8, 124.1, 125.9, 127.8, 128.6, 129.4, 133.7, 134.2, 140.0, 140.6, 151.4, 159.4, 164.5. IR (neat) ν_{max} 1151, 1309, 1459, 1616, 1674, 2991 cm^{-1} . HRMS[EI^+] calcd for $\text{C}_{20}\text{H}_{20}\text{N}_2\text{O}_4\text{S}$ [$\text{M}]^+$ 384.1144, found 384.1155.

3-Tosylquinolin-2(1*H*)-one (4ab)

Yield = 62%; white solid; mp \geq 300 °C; R_f = 0.1 (DCM : MeOH = 93 : 7); ^1H NMR (400 MHz, DMSO -*d*₆) δ 2.37 (s, 3H), 7.28 (m, 1H), 7.34 (d, J = 8.3 Hz, 1H), 7.40 (d, J = 8.2 Hz, 2H), 7.66 (m, 1H), 7.88–7.90 (m, 2H), 8.00 (d, J = 7.5 Hz, 1H), 8.94 (s, 1H), 12.22 (s, 1H). ^{13}C NMR (100 MHz, DMSO -*d*₆) δ 21.1, 115.3, 117.2, 122.7, 128.5, 129.4, 130.5, 131.0, 133.9, 136.7, 141.0, 144.2, 144.3, 156.4. IR (neat) ν_{max} 1149, 1315, 1556, 1620, 1657, 2830 cm^{-1} . HRMS[EI^+] calcd for $\text{C}_{16}\text{H}_{13}\text{NO}_3\text{S}$ [$\text{M}]^+$ 299.0616, found 299.0603.

3-((4-Methoxyphenyl)sulfonyl)quinolin-2(1*H*)-one (4ac)

Yield = 42%; pale yellow solid; mp 285–286 °C; R_f = 0.1 (DCM : MeOH = 93 : 7); ^1H NMR (400 MHz, DMSO -*d*₆) δ 3.84 (s, 3H), 7.10–7.13 (m, 2H), 7.29 (t, J = 7.5 Hz, 1H), 7.35 (d, J = 8.4 Hz, 1H), 7.67 (m, 1H), 7.93–7.95 (m, 2H), 8.00 (d, J = 8.0 Hz, 1H), 8.91 (s, 1H), 12.15 (s, 1H). ^{13}C NMR (100 MHz, DMSO -*d*₆) δ 55.8, 114.1, 115.3, 117.2, 122.7, 130.5, 130.9, 131.0, 131.4, 133.8, 140.9, 143.8, 156.4, 163.3. IR (neat) ν_{max} 1150, 1263, 1496, 1619, 1648, 2998 cm^{-1} . HRMS[EI^+] calcd for $\text{C}_{16}\text{H}_{13}\text{NO}_4\text{S}$ [$\text{M}]^+$ 315.0565, found 315.0569.

3-((4-Chlorophenyl)sulfonyl)quinolin-2(1*H*)-one (4ad)

Yield = 50%; off-white solid; mp 264–265 °C; R_f = 0.2 (DCM : MeOH = 93 : 7); ^1H NMR (400 MHz, DMSO -*d*₆) δ 7.29 (t, J = 7.6 Hz, 1H), 7.36 (d, J = 8.4 Hz, 1H), 7.66–7.70 (m, 3H), 8.02 (d, J = 8.2 Hz, 3H), 8.97 (s, 1H), 12.27 (s, 1H). ^{13}C NMR (100 MHz, DMSO -*d*₆) δ 115.4, 117.2, 122.8, 129.1, 130.2, 130.5, 130.7, 134.1, 138.4, 138.8, 141.1, 144.9, 156.4. IR (neat) ν_{max} 1162, 1321, 1476, 1619, 1651, 2828 cm^{-1} . HRMS[EI^+] calcd for $\text{C}_{15}\text{H}_{10}\text{ClNO}_3\text{S}$ [$\text{M}]^+$ 319.0070, found 319.0057.

3-((4-Fluorophenyl)sulfonyl)quinolin-2(1*H*)-one (4ae)

Yield = 55%; white solid; mp \geq 300 °C; R_f = 0.2 (DCM : MeOH = 93 : 7); ^1H NMR (400 MHz, DMSO -*d*₆) δ 7.29 (t, J = 7.5 Hz, 1H), 7.35 (d, J = 8.3 Hz, 1H), 7.43–7.48 (m, 2H), 7.68 (m, 1H), 8.02 (d, J = 7.8 Hz, 1H), 8.07–8.12 (m, 2H), 8.96 (s, 1H), 12.27 (s, 1H). ^{13}C NMR (100 MHz, DMSO -*d*₆) δ 115.4, 116.1 (d, $J_{\text{C},\text{F}}$ = 23 Hz), 117.2, 122.8, 130.5, 130.6, 131.8 (d, $J_{\text{C},\text{F}}$ = 10 Hz), 134.0, 135.8 (d, $J_{\text{C},\text{F}}$ = 3 Hz), 141.0, 144.7, 156.4, 165.0 (d, $J_{\text{C},\text{F}}$ = 251 Hz). ^{19}F NMR (376 MHz, DMSO -*d*₆) δ –104.9. IR (neat) ν_{max} 1147, 1319, 1488, 1621, 1657,

2829 cm^{-1} . HRMS[EI^+] calcd for $\text{C}_{15}\text{H}_{10}\text{FNO}_3\text{S}$ [$\text{M}]^+$ 303.0365, found 303.0361.

3-(Methylsulfonyl)quinolin-2(1*H*)-one (4af)

Yield = 53%; pale white solid; mp 277–278 °C; R_f = 0.2 (DCM : MeOH = 93 : 7); ^1H NMR (400 MHz, DMSO -*d*₆) δ 3.33 (s, 3H), 7.30 (t, J = 7.6 Hz, 1H), 7.40 (d, J = 8.3 Hz, 1H), 7.69 (m, 1H), 7.99 (m, 1H), 8.71 (s, 1H), 12.46 (s, 1H). ^{13}C NMR (100 MHz, DMSO -*d*₆) δ 41.4, 115.4, 117.2, 122.8, 130.4, 131.1, 133.8, 140.6, 143.2, 157.4. IR (neat) ν_{max} 1142, 1292, 1557, 1619, 1648, 2824 cm^{-1} . HRMS[EI^+] calcd for $\text{C}_{10}\text{H}_9\text{NO}_3\text{S}$ [$\text{M}]^+$ 223.0303, found 223.0320.

3-(Ethylsulfonyl)quinolin-2(1*H*)-one (4ag)

Yield = 50%; off-white solid; mp 242–243 °C; R_f = 0.15 (DCM : MeOH = 93 : 7); ^1H NMR (400 MHz, DMSO -*d*₆) δ 1.15 (t, J = 7.4 Hz, 3H), 3.52 (q, J = 7.4 Hz, 2H), 7.30 (t, J = 7.6 Hz, 1H), 7.40 (d, J = 8.3 Hz, 1H), 7.70 (m, 1H), 7.99 (d, J = 7.9 Hz, 1H), 8.72 (s, 1H), 12.46 (s, 1H). ^{13}C NMR (100 MHz, DMSO -*d*₆) δ 6.7, 46.8, 115.5, 117.3, 122.8, 128.9, 130.4, 133.9, 140.7, 144.6, 157.4. IR (neat) ν_{max} 1127, 1289, 1555, 1618, 1648, 2839 cm^{-1} . HRMS[EI^+] calcd for $\text{C}_{11}\text{H}_{11}\text{NO}_3\text{S}$ [$\text{M}]^+$ 237.0460, found 237.0456.

3-(Cyclopropylsulfonyl)quinolin-2(1*H*)-one (4ah)

Yield = 56%; pale yellow solid; mp \geq 300 °C; R_f = 0.25 (DCM : MeOH = 93 : 7); ^1H NMR (400 MHz, DMSO -*d*₆) δ 1.03–1.11 (m, 4H), 3.22 (m, 1H), 7.29 (t, J = 7.6 Hz, 1H), 7.40 (d, J = 8.3 Hz, 1H), 7.69 (t, J = 7.8 Hz, 1H), 7.96 (d, J = 7.9 Hz, 1H), 8.61 (s, 1H), 12.44 (s, 1H). ^{13}C NMR (100 MHz, DMSO -*d*₆) δ 5.1, 30.0, 115.4, 117.1, 122.8, 130.4, 130.7, 133.7, 140.6, 142.8, 157.4. IR (neat) ν_{max} 1142, 1287, 1618, 1654, 2867, 3006 cm^{-1} . HRMS[EI^+] calcd for $\text{C}_{12}\text{H}_{11}\text{NO}_3\text{S}$ [$\text{M}]^+$ 249.0460, found 249.0457.

3-(Cyclohexylsulfonyl)quinolin-2(1*H*)-one (4ai)

Yield = 27%; pale yellow solid; mp 268–269 °C; R_f = 0.2 (DCM : MeOH = 93 : 7); ^1H NMR (400 MHz, DMSO -*d*₆) δ 1.03–1.11 (m, 3H), 1.35–1.44 (m, 2H), 1.62 (d, J = 12.0 Hz, 1H), 1.79 (d, J = 12.6 Hz, 2H), 1.89 (d, J = 11.5 Hz, 2H), 3.72 (m, 1H), 7.29 (t, J = 7.5 Hz, 1H), 7.40 (d, J = 8.3 Hz, 1H), 7.69 (m, 1H), 7.98 (d, J = 7.9 Hz, 1H), 8.69 (s, 1H), 12.42 (s, 1H). ^{13}C NMR (100 MHz, DMSO -*d*₆) δ 24.2, 24.4, 24.9, 58.8, 115.4, 117.3, 122.8, 128.2, 130.3, 133.9, 140.7, 145.1, 157.4. IR (neat) ν_{max} 1127, 1303, 1480, 1620, 1642, 2927 cm^{-1} . HRMS[EI^+] calcd for $\text{C}_{15}\text{H}_{17}\text{NO}_3\text{S}$ [$\text{M}]^+$ 291.0929, found 291.0923.

3-((6-Methylpyridin-2-yl)sulfonyl)quinolin-2(1*H*)-one (4aj)

Yield = 26%; pale yellow solid; mp 275–276 °C; R_f = 0.2 (DCM : MeOH = 93 : 7); ^1H NMR (400 MHz, DMSO -*d*₆) δ 2.43 (s, 3H), 7.32 (t, J = 7.6 Hz, 1H), 7.37 (d, J = 8.3 Hz, 1H), 7.55 (m, 1H), 7.70 (m, 1H), 8.03–8.08 (m, 3H), 9.01 (s, 1H), 12.24 (s, 1H). ^{13}C NMR (100 MHz, DMSO -*d*₆) δ 23.7, 115.5, 117.2, 120.2, 122.9, 127.4, 129.1, 130.5, 134.1, 138.6, 141.0, 145.6, 156.4, 156.6, 159.0. IR (neat) ν_{max} 1117, 1313, 1452, 1619, 1649, 2840 cm^{-1} . HRMS[EI^+] calcd for $\text{C}_{15}\text{H}_{12}\text{N}_2\text{O}_3\text{S}$ [$\text{M}]^+$ 300.0569, found 300.0556.



3-(Thiophen-2-ylsulfonyl)quinolin-2(1*H*)-one (4ak)

Yield = 47%; off-white solid; mp ≥ 300 $^{\circ}\text{C}$; R_f = 0.2 (DCM : MeOH = 93 : 7). ^1H NMR (400 MHz, DMSO-*d*₆) δ 7.22 (t, *J* = 4.4 Hz, 1H), 7.29 (t, *J* = 7.6 Hz, 1H), 7.36 (d, *J* = 8.4 Hz, 1H), 7.68 (t, *J* = 7.8 Hz, 1H), 7.92 (d, *J* = 3.8 Hz, 1H), 8.01 (d, *J* = 8.0 Hz, 1H), 8.08 (d, *J* = 5.0 Hz, 1H), 8.92 (s, 1H), 12.35 (s, 1H). ^{13}C NMR (100 MHz, DMSO-*d*₆) δ 115.4, 117.1, 122.8, 127.8, 130.6, 131.1, 134.1, 135.4, 135.8, 140.2, 140.9, 143.9, 156.4. IR (neat) ν_{max} 1147, 1313, 1480, 1620, 1655, 2833 cm^{-1} . HRMS[EI^+] calcd for $\text{C}_{13}\text{H}_9\text{NO}_3\text{S}_2$ [M]⁺ 291.0024, found 291.0024.

3-(((7,7-Dimethyl-2-oxobicyclo[2.2.1]heptan-1yl)methyl)sulfonyl)quinolin-2(1*H*)-one (4al)

Eluent for the chromatography (Hex : EtOAc = 1 : 1); yield = 26%; white solid; mp 260–261 $^{\circ}\text{C}$; R_f = 0.2 (Hex : EtOAc = 1 : 1). ^1H NMR (400 MHz, DMSO-*d*₆) δ 0.81 (s, 3H), 1.01 (s, 3H), 1.38 (m, 1H), 1.57 (m, 1H), 1.86 (d, *J* = 18.4 Hz, 1H), 1.93 (m, 1H), 2.04 (t, *J* = 4.3 Hz, 1H), 2.26–2.32 (m, 2H), 3.45 (d, *J* = 15.2 Hz, 1H), 3.96 (d, *J* = 15.2 Hz, 1H), 7.29 (t, *J* = 7.5 Hz, 1H), 7.41 (d, *J* = 8.3 Hz, 1H), 7.69 (m, 1H), 7.98 (d, *J* = 7.8 Hz, 1H), 8.65 (s, 1H), 12.40 (s, 1H). ^{13}C NMR (100 MHz, DMSO-*d*₆) δ 19.3, 19.4, 24.7, 26.4, 41.8, 42.0, 48.0, 49.7, 58.4, 115.4, 117.3, 122.7, 130.4, 131.8, 133.7, 140.7, 143.1, 157.6, 214.1. IR (neat) ν_{max} 1138, 1314, 1626, 1646, 1746, 2954 cm^{-1} . HRMS[EI^+] calcd for $\text{C}_{19}\text{H}_{21}\text{NO}_4\text{S}$ [M]⁺ 359.1191, found 359.1187.

3-(Phenylthio)quinolin-2(1*H*)-one (5)

A 5 mL vial was charged with 2-bromobenzaldehyde **1a** (92.5 mg, 0.50 mmol), 2-iodoacetamide **2** (185.0 mg, 1.00 mmol), sodium thiophenoxide (90%, 146.8 mg, 1.00 mmol), Cu powder (60–80 nm, 6.4 mg, 0.10 mmol), 2-picolinic acid (12.3 mg, 0.10 mmol), K_2CO_3 (172.8 mg, 1.25 mmol) and $\text{Ca}(\text{OH})_2$ (92.6 mg, 1.25 mmol) in dry DMF (1.5 mL). The vial was sealed with the cap and heated at 110 $^{\circ}\text{C}$ under stirring for 48 h. After cooling to room temperature, the reaction mixture was diluted with saturated NH_4Cl solution and extracted with ethyl acetate (20 \times 5 mL). The combined organic solution was dried over MgSO_4 and concentrated, and subjected to silica gel column chromatography (DCM : MeOH = 97 : 3 to 95 : 5) to afford the quinolone **5** (69.7 mg, 55%).

Off-white solid; mp 241–242 $^{\circ}\text{C}$; R_f = 0.3 (DCM : MeOH = 93 : 7). ^1H NMR (400 MHz, DMSO-*d*₆) δ 7.11 (t, *J* = 7.5 Hz, 1H), 7.21 (s, 1H), 7.31 (d, *J* = 8.2 Hz, 1H), 7.41–7.45 (m, 2H), 7.48–7.56 (m, 5H), 12.14 (s, 1H). ^{13}C NMR (100 MHz, DMSO-*d*₆) δ 115.0, 119.3, 122.2, 126.8, 129.0, 129.5, 130.0, 130.7, 132.3, 133.4, 133.7, 136.9, 159.1. IR (neat) ν_{max} 1424, 1551, 1638, 1655, 2882, 2989 cm^{-1} . HRMS[EI^+] calcd for $\text{C}_{15}\text{H}_{11}\text{NOS}$ [M]⁺ 253.0561, found 253.0561.

General procedure for 6a–c

A 5 mL vial was charged with 2-bromobenzaldehyde **1a** (92.5 mg, 0.50 mmol), 2-iodoacetamide **2** (185.0 mg, 1.00 mmol), a corresponding sodium phenoxide (1.00 mmol), Cu powder (60–80 nm, 6.4 mg, 0.10 mmol), 2-picolinic acid

(12.3 mg, 0.10 mmol) and K_3PO_4 (265.3 mg, 1.25 mmol) in dry DMF (1.5 mL). The vial was sealed with the cap and heated at 110 $^{\circ}\text{C}$ under stirring for 48 h. After cooling to room temperature, the reaction mixture was diluted with saturated NH_4Cl solution and extracted with ethyl acetate (20 \times 5 mL). The combined organic solution was dried over MgSO_4 and concentrated, and subjected to silica gel column chromatography (Hex : EtOAc = 1 : 2 to 1 : 1) to afford the 2-quinolones.

3-Phenoxyquinolin-2(1*H*)-one (6a)

Yield = 37%; off-white solid; mp 209–210 $^{\circ}\text{C}$; R_f = 0.4 (Hex : EtOAc = 1 : 1). ^1H NMR (400 MHz, DMSO-*d*₆) δ 7.03–7.05 (m, 2H), 7.12 (t, *J* = 7.4 Hz, 1H), 7.18 (t, *J* = 7.5 Hz, 1H), 7.33–7.39 (m, 3H), 7.45 (m, 1H), 7.53 (s, 1H), 7.61 (d, *J* = 7.8 Hz, 1H), 12.13 (s, 1H). ^{13}C NMR (100 MHz, DMSO-*d*₆) δ 114.8, 117.3, 119.0, 122.1, 123.2, 123.7, 127.3, 128.9, 129.8, 136.1, 145.1, 156.4, 157.5. IR (neat) ν_{max} 1228, 1571, 1638, 1655, 2862, 3011 cm^{-1} . HRMS[EI^+] calcd for $\text{C}_{15}\text{H}_{11}\text{NO}_2$ [M]⁺ 237.0790, found 237.0802.

3-(4-Chlorophenoxy)quinolin-2(1*H*)-one (6b)

Yield = 51%; white solid; mp 220–221 $^{\circ}\text{C}$; R_f = 0.4 (Hex : EtOAc = 1 : 1). ^1H NMR (400 MHz, DMSO-*d*₆) δ 7.05–7.07 (m, 2H), 7.19 (m, 1H), 7.34–7.40 (m, 3H), 7.46 (m, 1H), 7.62–7.64 (m, 2H), 12.19 (s, 1H). ^{13}C NMR (100 MHz, DMSO-*d*₆) δ 114.9, 118.9, 118.9, 122.2, 124.8, 126.8, 127.5, 129.1, 129.6, 136.3, 144.5, 155.5, 157.3. IR (neat) ν_{max} 1226, 1430, 1479, 1654, 2854, 3013 cm^{-1} . HRMS[EI^+] calcd for $\text{C}_{15}\text{H}_{10}\text{ClNO}_2$ [M]⁺ 271.0400, found 271.0395.

3-(4-Methoxyphenoxy)quinolin-2(1*H*)-one (6c)

Yield = 28%; pale brown solid; mp 184–185 $^{\circ}\text{C}$; R_f = 0.2 (Hex : EtOAc = 1 : 1). ^1H NMR (400 MHz, DMSO-*d*₆) δ 3.75 (s, 3H), 6.95–6.98 (m, 2H), 7.03–7.06 (m, 2H), 7.13 (m, 1H), 7.22 (s, 1H), 7.31 (m, 1H), 7.40 (m, 1H), 7.54 (d, *J* = 7.9 Hz, 1H), 12.11 (s, 1H). ^{13}C NMR (100 MHz, DMSO-*d*₆) δ 55.4, 114.7, 115.0, 119.1, 119.8, 120.0, 122.1, 127.0, 128.3, 135.4, 147.0, 149.0, 155.7, 157.4. IR (neat) ν_{max} 1224, 1497, 1569, 1654, 2847, 2995 cm^{-1} . HRMS[EI^+] calcd for $\text{C}_{16}\text{H}_{13}\text{NO}_3$ [M]⁺ 267.0895, found 267.0895.

4-Methyl-3-(methyl(phenyl)amino)quinolin-2(1*H*)-one (7)

A 5 mL vial was charged with 2'-bromoacetophenone **1s** (99.5 mg, 0.50 mmol), 2-iodoacetamide **2** (138.7 mg, 0.75 mmol), *N*-methylaniline (0.08 mL, 0.75 mmol), CuI (19.0 mg, 0.10 mmol), 2-picolinic acid (6.2 mg, 0.05 mmol), K_2CO_3 (138.2 mg, 1.00 mmol) and $\text{Ca}(\text{OH})_2$ (74.1 mg, 1.00 mmol) in dry DMF (1.5 mL). The vial was sealed with the cap and heated at 110 $^{\circ}\text{C}$ under stirring for 48 h. After cooling to room temperature, the reaction mixture was diluted with saturated NH_4Cl solution and extracted with ethyl acetate (20 \times 5 mL). The combined organic solution was dried over MgSO_4 and concentrated, and subjected to silica gel column chromatography (Hex : EtOAc = 2 : 1 to 1 : 1) to afford the quinolone **7** (58.1 mg, 44%).

Pale yellow solid; mp 250–251 $^{\circ}\text{C}$; R_f = 0.3 (Hex : EtOAc = 1 : 1). ^1H NMR (400 MHz, DMSO-*d*₆) δ 2.31 (s, 3H), 3.12 (s, 3H), 6.51 (d, *J* = 8.1 Hz, 2H), 6.64 (t, *J* = 7.2 Hz, 1H), 7.10–7.14



(m, 2H), 7.23 (t, J = 7.6 Hz, 1H), 7.35 (d, J = 8.2 Hz, 1H), 7.51 (t, J = 7.7 Hz, 1H), 7.77 (d, J = 8.1 Hz, 1H), 11.85 (s, 1H). ^{13}C NMR (100 MHz, DMSO- d_6) δ 13.6, 37.4, 111.8, 115.2, 116.5, 119.7, 121.8, 125.4, 128.9, 129.9, 134.6, 137.4, 144.9, 148.2, 159.4. IR (neat) ν_{max} 1338, 1496, 1560, 1636, 2811, 2938 cm^{-1} . HRMS[EI^+] calcd for $\text{C}_{17}\text{H}_{16}\text{N}_2\text{O}$ [M^+] 264.1263, found 264.1270.

2-Chloro-3-(phenylsulfonyl)quinoline (8)

A mixture of compound **4aa** (42.8 mg, 0.15 mmol) in POCl_3 (0.35 mL, 3.75 mmol) was stirred at reflux for 1 h. Then, the reaction mixture was cooled to room temperature and quenched with ice-water. The mixture was neutralized with 1 N NaOH (15 mL) at 0 °C and extracted with EtOAc (10 \times 3 mL). The combined organic solution was dried over MgSO_4 , and concentrated. The residue was subjected to column chromatography (Hex : EtOAc = 6 : 1) to afford the quinoline **8** (43.4 mg, 95%) as a white solid.

Mp 150–151 °C; R_f = 0.4 (Hex : EtOAc = 5 : 1); ^1H NMR (400 MHz, CDCl_3 - d) δ 7.52–7.56 (m, 2H), 7.64 (t, J = 7.4 Hz, 1H), 7.71 (t, J = 7.6 Hz, 1H), 7.91 (m, 1H), 8.00–8.06 (m, 4H), 9.23 (s, 1H). ^{13}C NMR (100 MHz, CDCl_3 - d) δ 126.0, 128.6, 128.7, 129.0, 129.2, 129.4, 133.1, 133.9, 134.1, 139.3, 142.2, 145.4, 149.2. IR (neat) ν_{max} 1140, 1319, 1444, 1571, 2927, 3078 cm^{-1} . HRMS[EI^+] calcd for $\text{C}_{15}\text{H}_{10}\text{ClNO}_2\text{S}$ [M^+] 303.0121, found 303.0119.

1-Benzyl-3-(phenylsulfonyl)quinolin-2(1H)-one (9)

To a stirred solution of the compound **4aa** (285.3 mg, 1.00 mmol) in THF (10 mL) was added NaH (60% dispersed in mineral oil, 52.0 mg, 1.30 mmol) at 0 °C under N_2 . After 10 min, benzyl bromide (0.14 mL, 1.20 mmol) was added at 0 °C and the reaction mixture was stirred at room temperature for 1 h. Then, the reaction mixture was quenched with water and extracted with ethyl acetate. The combined organic solution was dried over MgSO_4 and concentrated. The residue was subjected to column chromatography (Hex : EtOAc = 4 : 1 to 3 : 2) to afford the product **9** (274 mg, 73%) as a white solid.

Mp 200–201 °C; R_f = 0.65 (Hex : EtOAc = 1 : 1); ^1H NMR (400 MHz, DMSO- d_6) δ 5.44 (s, 2H), 7.08 (d, J = 7.4 Hz, 2H), 7.18–7.27 (m, 3H), 7.36 (t, J = 7.5 Hz, 1H), 7.47 (d, J = 8.7 Hz, 1H), 7.60–7.64 (m, 2H), 7.68–7.73 (m, 2H), 8.04 (d, J = 7.7 Hz, 2H), 8.14 (d, J = 7.8 Hz, 1H), 9.09 (s, 1H). ^{13}C NMR (100 MHz, DMSO- d_6) δ 44.9, 115.5, 118.2, 123.1, 126.4, 127.2, 128.4, 128.6, 128.9, 130.0, 132.0, 133.7, 134.4, 136.0, 139.5, 140.9, 144.30, 156.2. IR (neat) ν_{max} 1143, 1285, 1440, 1559, 1636, 3066 cm^{-1} . HRMS[EI^+] calcd for $\text{C}_{22}\text{H}_{17}\text{NO}_3\text{S}$ [M^+] 375.0929, found 375.0940.

4-Allyl-1-benzyl-3-(phenylsulfonyl)-3,4-dihydroquinolin-2(1H)-one (10)

To a stirred solution of the compound **9** (75.1 mg, 0.20 mmol) in THF (2 mL) was added allyl magnesium bromide (1.0 M in ether, 0.30 mL, 0.30 mmol) at room temperature. After 1 h, the reaction mixture was quenched with water and extracted with EtOAc (5 \times 3 mL). The combined organic solution was dried over MgSO_4 , and concentrated. The residue was subjected to column chromatography (Hex : EtOAc = 4 : 1) to afford the product **10** (76.8 mg, 92%) as a white solid.

Mp 77–78 °C; R_f = 0.1 (Hex : EtOAc = 5 : 1); ^1H NMR (400 MHz, CDCl_3 - d) δ 2.28 (m, 1H), 2.40 (m, 1H), 3.83 (m, 1H), 4.24 (s, 1H), 4.99 (d, J = 8.2 Hz, 1H), 5.03 (d, J = 9.2 Hz, 1H), 5.12 (d, J = 10.2 Hz, 1H), 5.22 (d, J = 16.1 Hz, 1H), 5.70 (m, 1H), 6.80 (d, J = 8.1 Hz, 1H), 7.04 (t, J = 7.3 Hz, 1H), 7.11 (m, 1H), 7.21 (m, 1H), 7.27 (m, 1H), 7.32–7.40 (m, 6H), 7.55 (t, J = 7.5 Hz, 1H), 7.70 (d, J = 7.8 Hz, 2H). ^{13}C NMR (100 MHz, CDCl_3 - d) δ 37.2, 40.0, 47.0, 70.3, 116.0, 119.6, 124.1, 125.4, 126.9, 127.5, 128.4, 128.9, 128.9, 129.0, 133.2, 134.1, 136.3, 137.8, 138.2, 161.1. IR (neat) ν_{max} 1147, 1308, 1601, 1665, 2927, 3069 cm^{-1} . HRMS[EI^+] calcd for $\text{C}_{25}\text{H}_{23}\text{NO}_3\text{S}$ [M^+] 417.1399, found 417.1403.

3-(Tributylstanny)quinolin-2(1H)-one (11)

A mixture of compound **4aa** (42.8 mg, 0.15 mmol), AIBN (2.5 mg, 15 μmol), SnBu_3H (0.06 mL, 0.23 mmol) in dioxane (1.5 mL) was stirred at reflux for 30 h. Then, the reaction mixture was cooled to room temperature and concentrated. The residue was subjected to a short pad of silica gel (silica gel was pre-treated with 3% NEt_3 in DCM) and rinsed with DCM to afford the compound **11** (35.1 mg, 54%) as a white solid.

Mp 69–70 °C; R_f = 0.4 (DCM); ^1H NMR (400 MHz, CDCl_3 - d) δ 0.89–0.92 (m, 10H), 1.15–1.19 (m, 5H), 1.33–1.42 (m, 6H), 1.58–1.66 (m, 6H), 7.17 (t, J = 7.5 Hz, 1H), 7.35 (d, J = 8.2 Hz, 1H), 7.44 (m, 1H), 7.52 (d, J = 7.8 Hz, 1H), 7.89 (m, 1H), 12.39 (s, 1H). ^{13}C NMR (100 MHz, CDCl_3 - d) δ 10.1, 13.9, 27.6, 29.3, 116.0, 120.8, 122.1, 127.2, 130.0, 139.1, 139.4, 149.2, 167.8. IR (neat) ν_{max} 1424, 1611, 1626, 2849, 2914, 2952 cm^{-1} .

3-Chloroquinolin-2(1H)-one (12)

To a stirred solution of the compound **11** (43.4 mg, 0.10 mmol) in THF (1 mL) was added CuCl_2 (33.6 mg, 0.25 mmol) and 2,6-lutidine (10 μL , 0.10 mmol) at room temperature. After 1 h, the reaction mixture was quenched with saturated NaHCO_3 solution and extracted with EtOAc (5 \times 3 mL). The combined organic solution was dried over MgSO_4 , and concentrated. The residue was subjected to column chromatography (DCM : MeOH = 98 : 2) to afford the product **12** (16.0 mg, 89%) as a white solid.

Mp 252–253 °C; R_f = 0.1 (DCM); ^1H NMR (400 MHz, DMSO- d_6) δ 7.22 (t, J = 7.5 Hz, 1H), 7.34 (d, J = 8.3 Hz, 1H), 7.53 (t, J = 7.7 Hz, 1H), 7.67 (d, J = 7.9 Hz, 1H), 8.30 (s, 1H), 12.29 (s, 1H). ^{13}C NMR (100 MHz, DMSO- d_6) δ 115.2, 118.8, 122.4, 125.7, 127.4, 130.6, 137.7, 137.7, 157.6. IR (neat) ν_{max} 1203, 1429, 1637, 1654, 2921, 3006 cm^{-1} . HRMS[EI^+] calcd for $\text{C}_9\text{H}_6\text{ClNO}$ [M^+] 179.0138, found 179.0136.

3-Iodoquinolin-2(1H)-one (13)

A mixture of compound **11** (43.4 mg, 0.10 mmol), NaI (16.5 mg, 0.11 mmol), FeCl_3 (35.7 mg, 0.22 mmol) in $\text{THF}/\text{H}_2\text{O}$ (0.2 mL/0.2 mL) was stirred at rt for 1 h. Then, the reaction mixture was diluted with saturated NaHSO_3 solution and extracted with ethyl acetate (5 \times 3 mL). The combined organic solution was dried over MgSO_4 , and concentrated. The residue was subjected to column chromatography (DCM : MeOH = 98 : 2 to 97 : 3) to afford the product **12** (21.7 mg, 80%) as a white solid.



Mp 259–260 °C; R_f = 0.4 (Hex : EtOAc = 1 : 1); ^1H NMR (400 MHz, DMSO-*d*₆) δ 7.18 (t, *J* = 7.5 Hz, 1H), 7.31 (d, *J* = 8.3 Hz, 1H), 7.53 (t, *J* = 7.7 Hz, 1H), 7.64 (d, *J* = 7.9 Hz, 1H), 8.70 (s, 1H), 12.11 (s, 1H). ^{13}C NMR (100 MHz, DMSO-*d*₆) δ 95.9, 115.2, 120.3, 122.1, 127.0, 130.8, 138.8, 148.8, 158.8. IR (neat) ν_{max} 1210, 1421, 1627, 1637, 2922, 3122 cm⁻¹. HRMS[EI+] calcd for C₉H₆INO [M]⁺ 270.9494, found 270.9495.

N-(2-Formylphenyl)-2-iodoacetamide (II)

To a stirred solution of 2-iodoacetic acid (1.95 g, 10.5 mmol) in ethyl acetate (25 mL) was added 2-aminobenzaldehyde (1.21 g, 10.0 mmol) at 0 °C. Subsequently, *N,N'*-dicyclohexylcarbodiimide (2.06 g, 10.0 mmol) in EA (10 mL) was added dropwise to the mixture. After 30 min, the reaction mixture stirred at room temperature for 10 h. Then, the resulting slurry was filtered through a pad of Celite. The filtrate was concentrated and was subjected to column chromatography (Hex : EtOAc = 7 : 1) to afford the product **II** (1.38 g, 48%) as a pale yellow solid.

Mp 110–111 °C; R_f = 0.38 (Hex : EtOAc = 5 : 1); ^1H NMR (400 MHz, CDCl₃-*d*) δ 3.90 (s, 2H), 7.28 (m, 1H), 7.64 (t, *J* = 8.0 Hz, 1H), 7.71 (d, *J* = 7.7 Hz, 1H), 8.68 (d, *J* = 8.5 Hz, 1H), 9.94 (s, 1H), 11.52 (s, 1H). ^{13}C NMR (100 MHz, CDCl₃-*d*) δ -0.1, 120.0, 122.0, 123.7, 136.1, 136.3, 140.5, 167.0, 195.6. IR (neat) ν_{max} 1074, 1192, 1290, 1444, 1653, 3231 cm⁻¹.

Conflicts of interest

There are no conflicts to declare.

Acknowledgements

Financial support from the KRICT, Republic of Korea (SI1935-10) and the National Research Foundation of Korea (NRF-2019R1C1C1004970) are greatly appreciated. Prof. Michael Young (The University of Toledo) is acknowledged for proofreading the manuscript.

Notes and references

- (a) B. Joseph, F. Darro, A. Behard, B. Lesur, F. Collignon, C. Decaestecker, A. Frydman, G. Guillaumet and R. Kiss, *J. Med. Chem.*, 2002, **45**, 2543; (b) J. Shi, Z. Xiao, M. A. Ihnat, C. Kamat, B. Pandit, Z. Hu and P. K. Li, *Bioorg. Med. Chem. Lett.*, 2003, **6**, 1187; (c) S. Pasquini, M. De Rosa, V. Pedani, C. Mugnaini, F. Guida, L. Luongo, M. De Chiaro, S. Maione, S. Dragoni, M. Frosini, A. Ligresti, V. Di Marzo and F. Corelli, *J. Med. Chem.*, 2011, **54**, 5444; (d) A. A. Al-Amiry, R. I. H. Al-Bayati, K. Y. Saour and M. F. Radi, *Res. Chem. Intermed.*, 2012, **38**, 559; (e) Y. Zhang, Y. Fang, H. Liang, H. Wang, K. Hu, X. Liu, X. Yi and Y. Peng, *Bioorg. Med. Chem. Lett.*, 2013, **23**, 107; (f) S. K. Suthar, V. Jaiswal, S. Lohan, S. Bansal, C. Chaudhary, A. Tiwari, A. T. Alex and A. Joseph, *Eur. J. Med. Chem.*, 2013, **63**, 589; (g) T. Tashima, *Bioorg. Med. Chem. Lett.*, 2015, **25**, 3415; (h) T. Shiro, T. Fukaya and M. Tobe, *Eur. J. Med. Chem.*, 2015, **97**, 397.

- (a) W. M. F. Fabian, K. S. Niederreiter, G. Uray and W. Stadlbauer, *J. Mol. Struct.*, 1999, **477**, 209; (b) N. S. Badgujar, M. Pazicky, P. Traar, A. Terec, G. Uray and W. Stadlbauer, *Eur. J. Org. Chem.*, 2006, 2715; (c) T. L. Micotto, A. S. Brown and J. N. Wilson, *Chem. Commun.*, 2009, 7548; (d) R. S. Singh, A. Kumar, S. Mukhopadhyay, G. Sharma, B. Koch and D. S. Pandey, *J. Phys. Chem. C*, 2016, **120**, 22605; (e) A. Joliton, J.-M. Plancher and E. M. Carreira, *Angew. Chem., Int. Ed.*, 2016, **55**, 2113; (f) A. S. Murugan, N. Vidhyalakshmi, U. Yamesh and J. Annaraj, *J. Mater. Chem. B*, 2017, **5**, 3195.
- (a) M. F. Grundon, in *The Alkaloids: Quinoline Alkaloids Related to Anthranilic Acid*, Academic Press, London, 1988, vol. 32, p. 341; (b) J. P. Michael, *Nat. Prod. Rep.*, 1995, **12**, 465; (c) S. D. Sarker and P. G. Waterman, *J. Nat. Prod.*, 1995, **58**, 574; (d) C. Ito, M. Itoigawa, A. Furukawa, T. Hirano, T. Murata, N. Kaneda, Y. Hisada, K. Okuda and H. Furukawa, *J. Nat. Prod.*, 2004, **67**, 1800.
- (a) B. Staskun, *J. Org. Chem.*, 1964, **29**, 1153; (b) K. Kumar, S. Sai, T. M. Gilbert and D. Klumpp, *J. Org. Chem.*, 2007, **72**, 9761.
- C.-C. Cheng and S.-J. Yan, *Organic Reactions*, John Wiley and Sons, New York, 1982, vol. 28, p. 37.
- (a) K. H. Raitio, J. R. Savinainen, J. Vepsäläinen, J. T. Laitinen, A. Poso, T. Järvinen and T. J. Nevalainen, *J. Med. Chem.*, 2006, **49**, 2022; (b) B. F. McGuinness, K.-K. Ho, T. M. Stauffer, L. L. Rokosz, N. Mannava, S. G. Kultgen, K. Saionz, A. Klon, W. Chen, H. Desai, W. L. Rogers, M. Webb, J. Yin, Y. Jiang, T. Li, H. Yan, K. King, S. Zahng, K. K. Majmadar, V. Srivastava and S. Saha, *Bioorg. Med. Chem. Lett.*, 2010, **20**, 7414.
- (a) D. V. Kadnikov and R. C. Larock, *J. Org. Chem.*, 2004, **69**, 6772; (b) J. Ferguson, F. Zeng, N. Alwis and H. Alper, *Org. Lett.*, 2013, **15**, 1998; (c) X. Li, X. Li and N. Jiao, *J. Am. Chem. Soc.*, 2015, **137**, 9246; (d) F. Zhu, Y. Li, Z. Wang and X.-F. Wu, *Adv. Synth. Catal.*, 2016, **358**, 3350; (e) V. Thakur, A. Sharma, Yamini, N. Sharma and P. Das, *Adv. Synth. Catal.*, 2019, **361**, 426.
- (a) R. Manikandan and M. Jeganmohan, *Org. Lett.*, 2014, **16**, 3568; (b) J. Wu, S. Xiang, J. Zeng, M. Leow and X.-W. Liu, *Org. Lett.*, 2015, **17**, 222; (c) R. Kancherla, T. Naveen and D. Maiti, *Chem.-Eur. J.*, 2015, **21**, 8360; (d) Z. Zhang, L.-L. Liao, S.-S. Yan, L. Wang, Y.-Q. He, J.-H. Ye, J. Li, Y.-G. Zhi and D.-G. Yu, *Angew. Chem., Int. Ed.*, 2016, **55**, 7068.
- R. Zeng and G. Dong, *J. Am. Chem. Soc.*, 2015, **137**, 1408.
- (a) Y. Dong, B. Liu, P. Chen, Q. Liu and M. Wang, *Angew. Chem., Int. Ed.*, 2014, **53**, 3442; (b) W. Wang, X. Peng, X. Qin, X. Zhao, C. Ma, C.-H. Tung and Z. Xu, *J. Org. Chem.*, 2015, **80**, 2835.
- For use of pre-functionalized acetamides, (a) P. J. Manley and M. T. Bilodeau, *Org. Lett.*, 2004, **6**, 2433; (b) L. Fu, X. Huang, D. Wang, P. Zhao and K. Ding, *Synthesis*, 2011, **10**, 1547; (c) B. H. Ahn, I. Y. Lee and H. N. Lim, *Org. Biomol. Chem.*, 2018, **16**, 7851.
- For recent reviews for the copper catalyzed multicomponent reaction, see: (a) S. Hassan and T. J. J. Mueller, *Adv. Synth. Catal.*, 2015, **357**, 617; (b) N. K. Ojha, G. V. Zyryanov,



A. Majee, V. N. Charushin, O. N. Chupakhin and S. Santra, *Coord. Chem. Rev.*, 2017, **353**, 1; (c) S. B. Sing, *Curr. Catal.*, 2018, **7**, 80; (d) R. Rossi, G. Angelici, G. Casotti, C. Manzini and M. Lessi, *Adv. Synth. Catal.*, 2019, **361**, 2737; (e) A. Cherian, N. A. Harry, S. Saranya, K. R. Rohit and G. Anilkumar, *Asian J. Org. Chem.*, 2019, **8**, 197.

13 M. Nallagangula and K. Namitharan, *Org. Lett.*, 2017, **19**, 3536.

14 (a) A. Klapars, X. Huang and S. L. Buchwald, *J. Am. Chem. Soc.*, 2002, **124**, 7421; (b) J. C. Antilla, A. Klapars and S. L. Buchwald, *J. Am. Chem. Soc.*, 2002, **124**, 11684; (c) J. C. Antilla, J. M. Baskin, T. E. Barder and S. L. Buchwald, *J. Org. Chem.*, 2004, **69**, 6514; (d) E. R. Strieter, D. G. Blackmond and S. L. Buchwald, *J. Am. Chem. Soc.*, 2005, **127**, 4120; (e) D. S. Surry and S. L. Buchwald, *Chem. Sci.*, 2010, **1**, 13.

15 (a) S. Ley and A. W. Thomas, *Angew. Chem., Int. Ed.*, 2003, **42**, 5400; (b) I. P. Beletskaya and A. V. Cheprakov, *Coord. Chem. Rev.*, 2004, **248**, 2337; (c) A. Shafir, P. Lichtor and S. L. Buchwald, *J. Am. Chem. Soc.*, 2007, **129**, 3490; (d) F. Monnier and M. Taillefer, *Angew. Chem., Int. Ed.*, 2008, **47**, 3096; (e) F. Monnier and M. Taillefer, *Angew. Chem., Int. Ed.*, 2009, **48**, 6954; (f) A. Casita and X. Ribas, *Chem. Sci.*, 2013, **4**, 2301; (g) C. Sambiagio, S. P. Marsden, A. J. Blacker and P. C. McGowan, *Chem. Soc. Rev.*, 2014, **43**, 3525.

16 The exact reason for the low yields in comparison with the control (entry 3) is not clear at this point. However, it cannot be excluded that the ligands **L5** and **L6** react with the substrates **1a** and **2**, which leads to the formation of many intractable side products.

17 No condensation product between **1a** and **L8** was detected, presumably due to the steric hindrance of t-butyl group.

18 (a) A. U. Meyer, K. Straková, T. Slanina and B. König, *Chem.-Eur. J.*, 2016, **22**, 8694; (b) T. Markovic, B. N. Rocke, D. C. Blakemore, V. Mascitti and M. C. Willis, *Org. Lett.*, 2017, **19**, 6033; (c) G. Bogonda, D. V. Patil, H. Y. Kim and K. Oh, *Org. Lett.*, 2019, **21**, 3774.

19 When **1a** was used, many intractable side-products were observed. Gratifyingly, the ketone substrate turned out to be better suited to the secondary amine than aldehyde. In addition, use of CuI (20 mol%) and picolinic acid (10 mol%) was more efficient than that of copper powder (29%).

20 T.-H. Tsai, W.-H. Chung, J.-K. Chang, R.-T. Hsu and N.-C. Chang, *Tetrahedron*, 2007, **63**, 9825.

21 S. Caddick and S. Khan, *Tetrahedron Lett.*, 1993, **34**, 7469.

22 M. Heinrich, J. J. Murphy, M. K. Ilg, A. Letort, J. Flasz, P. Philipps and A. Fürstner, *Angew. Chem., Int. Ed.*, 2018, **57**, 13575.

23 D. W. Blevins, M.-L. Yao, L. Yong and G. W. Kabalka, *Tetrahedron Lett.*, 2015, **56**, 3130.

24 (a) V. J. K. Stille, *Angew. Chem.*, 1986, **98**, 504; (b) M. S. Holt, W. L. Wilson and J. H. Nelson, *Chem. Rev.*, 1989, **89**, 11.

25 Halogen exchange with NaI in aryl bromides under the Cu(I) catalyst was reported, see: A. Klapars and S. L. Buchwald, *J. Am. Chem. Soc.*, 2002, **124**, 14844.

